Iovance Biotherapeutics Inc. experienced a significant surge in its stock price, rising by 15.57% to close at $4.38 on Thursday, June 4, 2026, following the conditional approval of its melanoma treatment, Amtagvi, by Australia’s Therapeutic Goods Administration (TGA). This marks the third marketing authorization for Amtagvi, which has already received approvals in the United States and Canada.
The approval is particularly noteworthy as Australia has the highest melanoma incidence rate globally, with approximately 17,000 new cases and over 1,500 related deaths each year. Frederick Vogt, President and CEO of Iovance Biotherapeutics, emphasized the importance of this milestone, stating it represents a significant advancement for the company in a region heavily affected by melanoma.
Iovance is currently in the process of establishing its first treatment center in Australia as part of its strategy to expand Amtagvi into additional markets with high rates of advanced melanoma. The TGA's approval was based on positive safety and efficacy results from the global, multicenter C-144-01 trial, which evaluated Amtagvi in patients with advanced melanoma who had previously undergone anti-PD-1 therapy and, where applicable, targeted therapy.
Leave a comment